Allergy Therapeutics plc
AGYTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.08 | 0.22 | 0.00 |
| FCF Yield | -10.62% | -4.66% | -10.13% | -59.09% |
| EV / EBITDA | -9.31 | -53.23 | -10.71 | -1.89 |
| Quality | ||||
| ROIC | -60.92% | -17.76% | -50.37% | -26.09% |
| Gross Margin | 32.83% | 61.30% | 42.62% | 61.12% |
| Cash Conversion Ratio | 0.73 | 0.69 | 0.87 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.99% | -11.89% | -8.92% | -7.95% |
| Free Cash Flow Growth | -239.60% | 59.70% | -81.19% | 49.71% |
| Safety | ||||
| Net Debt / EBITDA | -1.17 | -5.50 | -0.80 | 0.39 |
| Interest Coverage | -3.39 | -3.13 | 0.00 | -1.86 |
| Efficiency | ||||
| Inventory Turnover | 1.46 | 1.11 | 0.97 | 1.10 |
| Cash Conversion Cycle | 70.85 | 6.66 | 93.62 | -29.88 |